Here, we focused our study on ACMG-recommended genes and high penetrance genes known to be associated with PHTS component cancers because they have well-established cancer risks and clinical management guidelines that could lead to gene-specific risk assessments and management, instead of merely following PHTS guidelines in the absence of PTEN mutations. The gene discussed is PTEN; the disease is cancer.